文献速递生殖医学

髓过氧化物酶抑制剂AZD5904在体外改善人类精子功能

Myeloperoxidase inhibitor AZD5904 enhances human sperm function in vitro.
PubMed 文献 · Hum Reprod · 2021-01-01

本研究利用中性粒细胞激活构建体外氧化应激模型,将45例男性精液样本与髓过氧化物酶抑制剂AZD5904共孵育,评估其对精子活力的影响。结果显示总活力与前向运动力无显著差异,但16/45(35.6%)样本的精子穿透黏性介质能力提升≥20%(P < 0.003)。提示AZD5904可能改善氧化应激下的精子功能。

要点

  • AZD5904在体外氧化应激模型中可改善精子穿透功能。
  • 总活力与前向运动力在各组间无显著差异。
  • 35.6%样本精子穿透黏性介质提升≥20%(P < 0.003)。

核心结论

  • AZD5904在体外氧化应激模型中改善精子功能,可能为男性不育提供新治疗思路。

研究设计与样本

  • 研究纳入2017年7月至2018年9月在邓迪Ninewells辅助生殖中心行诊断性精液分析的23-50岁男性,使用45例患者的47份精液样本。

主要发现

  • 在2小时和24小时,任何治疗组与对照组的总精子活力或前向运动力均无显著差异。
  • AZD5904处理组中16/45(35.6%)样本(含基線精液分析正常与异常者)精子穿透黏性介质能力提升≥20%(P < 0.003)。

临床怎么用

  • 目前仅为体外研究,尚不能直接用于临床治疗男性不育。

局限性

  • 本研究为体外研究,结论需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does AZD5904, a myeloperoxidase inhibitor (MPOi), have any effect on human sperm function in vitro? SUMMARY ANSWER: AZD5904 improves sperm function in an in vitro model of oxidative stress (OS) and potentially offers a novel treatment approach for male infertility. WHAT IS KNOWN ALREADY: Male infertility is an underlying or contributory cause in half of all couples experiencing difficulties conceiving, yet there is currently no effective treatment or cure. OS is a common pathology in a significant proportion of infertile men. It can negatively affect sperm motility and the ability to fertilize a mature oocyte, as well as DNA integrity, and therefore represents an attractive target for therapeutic intervention. STUDY DESIGN, SIZE, DURATION: This study included population-based samples from men (23-50 years) attending Ninewells Assisted Conception Unit, Dundee for diagnostic semen analysis, July 2017-September 2018. Semen samples (n = 47) from 45 patients were used. PARTICIPANTS/MATERIALS, SETTING, METHODS: Neutrophils activated using zymosan were incubated with prepared human spermatozoa for 2 h (T2) and 24 h (T24) to create an in vitro model of OS. Parallel samples were co-incubated with AZD5904, an MPOi, to examine its effects. Sperm motility was assessed by computer-assisted sperm analysis at T2 and T24. Functional motility was assessed by sperm penetration assay. Statistical analysis was performed using GraphPad Prism. MAIN RESULTS AND THE ROLE OF CHANCE: There was no significant difference in total or progressive sperm motility between any treatment and control groups at T2 or T24. Nonetheless, significant positive effects on sperm function were observed with AZD5904, with 16/45 (35.6%) samples (with both normal and abnormal baseline semen analysis characteristics) displaying a ≥20% increase in sperm penetrated through viscous media (P < 0.003). LIMITATIONS, REASONS FOR CAUTION: This was an in vitro study. WIDER IMPLICATIONS OF THE FINDINGS: Treatment with AZD5904 resulted in significant increased sperm penetration in one of three samples treated, which is likely to represent improvement in sperm function required for fertilization. We are now planning a clinical trial to validate these results and hope that this could represent a new treatment for male infertility. STUDY FUNDING/COMPETING INTEREST(S): AZD5904 was shared through the AstraZeneca Open Innovation program. The study was funded by AstraZeneca and sponsored by the University of Dundee. Additional funding was provided by Chief Scientist Office/NHS Research Scotland (S.J.M.d.S.). A.W. and H.J.S. are both full time employees of AstraZeneca. A.W. and H.J.S. are inventors on a patent filed by AstraZeneca titled MPOi for use in medicine which includes MPOi for use in the treatment of male infertility (WO 2019/016074 Al). S.J.M.d.S. is Associate Editor of Human Reproduction and Editorial Board member of Reproduction & Fertility. C.L.R.B. is Editor of RBMO and has received lecturing fees from Merck and Ferring and is on the Scientific Advisory Panel for Ohana BioSciences. C.L.R.B. was chair of the World Health Organization Expert Synthesis Group on Diagnosis of Male infertility (2012-2016). C.L.R.B. has a patent WO2013054111 A1 issued. The other authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Campbell MJ, Sucquart IE, Whittaker A, et al. Myeloperoxidase inhibitor AZD5904 enhances human sperm function in vitro. Hum Reprod. 2021. PMID: 33393586. doi:10.1093/humrep/deaa328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。